Inversago Pharma
is a Canada-based biotechnology company that researches and develops CB1 antagonist drugs for the treatment of lung fibrosis and diabetic kidney diseases... Read moreInversago Pharma
is a Canada-based biotechnology company that researches and develops CB1 antagonist drugs for the treatment of lung fibrosis and diabetic kidney diseases... Read more
News
Apr 19, 2024
PRWeb
Press Release: Inversago Pharma : EY Announces Marc Laplante of Intentsify as an Entrepreneur Of The Year 2024 New England Award Finalist
Apr 18, 2024
Pharamceutical Technology
Inversago Pharma: Monlunabant by Inversago Pharma for Obesity: Likelihood of Approval
Feb 20, 2024
Pharamceutical Technology
Inversago Pharma: INV-347 by Inversago Pharma for Obesity: Likelihood of Approval
Sep 06, 2023
Global Legal Chronicle
Inversago Pharma: Inversago Pharma's $1.075 Billion Business Combination with Novo Nordisk
Aug 18, 2023
Betakit
Inversago Pharma: H|T: The Healthtech Times - Ozempic maker Novo Nordisk buys Montral's Inversago for $1 billion
Aug 14, 2023
European Biotechnology
Inversago Pharma: Novo Nordisk takes over Inversago Pharma Inc.
Aug 11, 2023
Beckers Hospital Review
Inversago Pharma: Novo Nordisk to buy obesity drugmaker for up to $1B
Aug 11, 2023
BioCentury
Inversago Pharma: Novo's Inversago takeout brings another appetite and glucose modulator to its obesity arsenal
Aug 10, 2023
Financial Post
Inversago Pharma: Montreal biotech with 'promising' weight-loss drug acquired by Ozempic maker
Aug 10, 2023
CNBC
Inversago Pharma: Novo Nordisk to acquire obesity drug maker Inversago Pharma for up to $1 billion
Inversago Pharma Competitors
1
2
3
4
5
6
7
8
9